双靶向MCL1与NOXA是治疗套细胞淋巴瘤的有效策略
本研究探讨联合脂肪酸合成酶抑制剂(稳定NOXA)与CDK抑制剂Dinaciclib(降低MCL1)双靶向NOXA/MCL1轴的效果。该联合在细胞系和原代MCL细胞中协同诱导凋亡,并在小鼠模型中几乎完全抑制肿瘤进展;凋亡依赖NOXA且与NOXA/MCL1比值相关。
要点
- 脂肪酸合成酶抑制剂与Dinaciclib联合在MCL细胞中协同诱导凋亡。
- 该联合在小鼠模型中几乎完全抑制肿瘤进展。
- 凋亡依赖NOXA且与NOXA/MCL1比值相关。
核心结论
- 双靶向NOXA/MCL1轴是治疗套细胞淋巴瘤的有效策略。
研究设计与样本
- 研究在套细胞淋巴瘤细胞系、原代MCL细胞和小鼠模型中评估脂肪酸合成酶抑制剂与CDK抑制剂Dinaciclib联合靶向NOXA/MCL1轴的效果。
主要发现
- 脂肪酸合成酶抑制剂与Dinaciclib联合在细胞系和原代MCL细胞中协同诱导凋亡。
- 该联合在小鼠模型中导致几乎完全抑制肿瘤进展。
- 凋亡依赖NOXA且与NOXA/MCL1比值相关。
关键数值与推荐
- 凋亡依赖NOXA且与NOXA/MCL1比值相关,凸显NOXA/MCL1平衡对MCL有效诱导细胞死亡的重要性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Imbalances in the composition of BCL2 family proteins contribute to tumourigenesis and therapy resistance of mantle cell lymphoma (MCL), making these proteins attractive therapy targets. We studied the efficiency of dual targeting the NOXA/MCL1 axis by combining fatty acid synthase inhibitors (NOXA stabilization) with the CDK inhibitor Dinaciclib (MCL1 reduction). This combination synergistically induced apoptosis in cell lines and primary MCL cells and led to almost complete inhibition of tumour progression in a mouse model. Apoptosis was NOXA-dependent and correlated with the NOXA/MCL1 ratio, highlighting the importance of the NOXA/MCL1 balance for effective cell death induction in MCL.
引用
- Höring E, Montraveta A, Heine S, et al. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. Br J Haematol. 2017. PMID: 28295185. doi:10.1111/bjh.14571
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。